摘要
目的探讨宁胃胶囊联合奥美拉唑治疗消化性溃疡的临床疗效。方法选取医院2021年1月至2023年1月收治的消化性溃疡患者120例,采用随机数字表法分为观察组和对照组,各60例。两组患者均口服奥美拉唑肠溶胶囊,观察组患者加服宁胃胶囊。两组均持续治疗4周。结果观察组总有效率为95.00%,显著高于对照组的83.33%(P<0.05)。两组患者治疗后的中医证候(脘胁胀满、泛吐酸水、情志抑郁、胃脘嘈杂、脉弦、胸闷食少)积分,基础胃酸分泌量、最大胃酸分泌量、高峰胃酸分泌量均显著减少,血清血管内皮生长因子(VEGF)、碱性成纤维细胞生长因子(bFGF)水平均显著升高(P<0.05),且观察组上述指标改善更显著(P<0.05)。观察组与对照组不良反应发生率相当(16.67%比13.33%,P>0.05)。结论宁胃胶囊联合奥美拉唑治疗消化性溃疡,可有效改善患者中医症状,减少胃酸分泌,并提高血清VEGF、bFGF水平。
Objective To investigate the clinical efficacy of Ningwei Capsules combined with omeprazole in the treatment of peptic ulcer.Methods A total of 120 patients with peptic ulcer admitted to the hospital from January 2021 to January 2023 were selected and divided into the observation group and the control group by the random number table method,with 60 cases in each group.The patients in the two groups were given oral Omeprazole Enteric Capsules,on this basis,the patients in the observation group were given oral Ningwei Capsules.Both groups were treated continuously for four weeks.Results The total effective rate in the observation group was 95.00%,which was significantly higher than 83.33%in the control group(P<0.05).After treatment,the scores of traditional Chinese medicine(TCM)syndromes(abdominal distension,acid regurgitation,depression,gastric noise,string pulse,chest distress,eating a little)in the two groups significantly decreased,the basal acid output(BAO),maximal acid output(MAO)and peak acid output(PAO)significantly decreased,the serum vascular endothelial growth factor(VEGF)and basic fibroblast growth factor(bFGF)levels significantly increased(P<0.05);and the above indexes in the observation group were significantly better(P<0.05).The incidence of adverse reactions in the observation group was similar to that in the control group(16.67%vs.13.33%,P>0.05).Conclusion Ningwei Capsules combined with omeprazole can effectively improve the TCM symptoms,decrease the gastric acid secretion,and increase the serum VEGF and bFGF levels in patients with peptic ulcer.
作者
杨宇成
袁宇婷
刘海云
张鹏
干定云
YANG Yucheng;YUAN Yuting;LIU Haiyun;ZHANG Peng;GAN Dingyun(Rugao People's Hospital,Nantong,Jiangsu,China 226500;The Third Hospital of Wuhan,Wuhan,Hubei,China 430074)
出处
《中国药业》
CAS
2024年第16期109-112,共4页
China Pharmaceuticals
基金
湖北省卫生健康委员会科研项目[WJ2021M012]。